Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Exclusion Criteria

• •Intervention with any chemotherapy, investigational agents or other anti-cancer drugs within 14 days or 5 half-lives of the first dose
• •Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study treatment
• •Strong inhibitors of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
• •Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment
• •Patients should discontinue statins prior to starting study treatment
• •CYP2C8 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
• •Any unresolved reversible toxicities from prior therapy \>CTCAE grade 1 at the time of starting study treatment (except alopecia and grade 2 neuropathy)
• •Any evidence of severe or uncontrolled systemic diseases
• •Any known uncontrolled inter-current illness
• •QTcF prolongation (\> 470 msec)